A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (NCT04974398)
A Randomized, Double-blind, Multi-center Phase III Study of Penpulimab (AK105) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
🩺 Plain-English Summary (8th-Grade Level)
This study is a randomized, double-blind, multi-center phase III clinical study to compare the efficacy and safety of penpulimab combined with chemotherapy and placebo combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 12 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (56 Sites)
Showing the first 25 of 56 sites.
- City of Hope — Duarte, California
- Winship Cancer Institute/Emory University — Atlanta, Georgia
- University of Michigan — Ann Arbor, Michigan
- Icahn School of Medicine at Mount Sinai — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Chris O'Brien Lifehouse — Camperdown, New South Wales
- St Vincent's Public Hospital Sydney — Darlinghurst, New South Wales
- Genesis Care North Shore — St Leonards, New South Wales
- Sir Charles Gardner — Heidelberg, Victoria
- Austin Health — Nedlands, Western Australia
- Hospital de Câncer de Barretos - Fundação Pio XII — Barretos, REG1
- Grupo Oncoclínicas — Botafogo, REG1
- Hospital Bruno Born — Lajeado, REG1
- Hospital Nossa Senhora da Conceicao — Porto Alegre, REG1
- Centro de Estudos e Pesquisa de Hematologia — Santo André, REG1
- Instituto do Câncer do Estado de São Paulo (ICESP) — São Paulo, REG1
- Centro de Câncer A. C. Camargo — São Paulo, REG1
- Alberta Health Services (Tom Baker Cancer Centre) — Calgary, Alberta
- Toronto Sunnybrook Hospital — Toronto, Ontario
- The First Affiliated Hospital of Anhui Medical University — Hefei, Anhui
- Fujian Cancer Hospital — Fuzhou, Fujian
- The First Affiliated Hospital of Xiamen University — Xiamen, Fujian
- Dongguan People's Hospital — Dongguan, Guangdong
- The First Affiliated Hospital of Sun Yat-sen University — Guangzhou, Guangdong
- Affiliated Cancer Hospital and Institute of Guangzhou Medical University — Guangzhou, Guangdong
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Nasopharyngeal Carcinoma
- Nasopharyngeal Carcinoma Post IMRT — Toronto, Ontario
- A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma — Basking Ridge, New Jersey
- Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma — San Francisco, California
- Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC) — Palo Alto, California
Explore by condition: All Nasopharyngeal Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.